Open an account

Outlook Therapeutics

OTLK · NASDAQ

$0.52+$0.027 (+5.48%)TodayMarket closed ·
Prev close $0.493

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Employees
17
Headquarters
Iselin, New Jersey
Listed
Jun 13, 2016
Sector
Health Care
Industry
Biotechnology
Website
outlooktherapeutics.com

OTLK key statistics

Market cap
126.59M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.33M
Volume
3.31M
Open price
$0.50
High today
$0.60
Low today
$0.50
52 Week high
$2.54
52 Week low
$0.1611

Outlook Therapeutics (OTLK) at a glance

As of Oct 20, 2026, Outlook Therapeutics (OTLK) shares are priced at $0.52, giving the company a market cap of 126.59M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.50 and $0.60. The current price is 4.0% above the day's low and 13.3% below its high.

Volume so far is 3.31M shares, below the average of 4.33M shares a day.

Over the past year Outlook Therapeutics has ranged from $0.1611 to $2.54, and now sits 15% of the way up that range.

Outlook Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY26 it reported -$0.09 per share against an estimate of -$0.0884.

The average analyst price target is $5.13, 885.7% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 4 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 6 analystsAvg $5.13
Low
$1.62
Now
$0.52
High
$11.02

OTLK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 110.3% on average.

  1. Q4 FY24: reported $0.76 per share against an estimate of -$0.8507
  2. Q1 FY25: reported $0.72 per share against an estimate of -$0.7905
  3. Q2 FY25: reported -$0.40 per share against an estimate of -$0.61
  4. Q3 FY25: reported -$0.55 per share against an estimate of -$0.4012
  5. Q4 FY25: reported -$0.19 per share against an estimate of -$0.2584
  6. Q1 FY26: reported -$0.22 per share against an estimate of -$0.1768
  7. Q2 FY26: reported -$0.16 per share against an estimate of -$0.1224
  8. Q3 FY26: reported -$0.09 per share against an estimate of -$0.0884

OTLK news

  • Press releaseGlobe Newswire

    Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

  • Avi Kapoor

    5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Vandana Singh

    Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

  • Press releaseGlobe Newswire

    Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Similar companies

Companies in the same industry as Outlook Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.